Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, United States.
Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, United States.
Crit Rev Oncol Hematol. 2020 Aug;152:103007. doi: 10.1016/j.critrevonc.2020.103007. Epub 2020 May 29.
Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the field of hematologic malignancies and are potentially curative in patients with previously limited options. This review highlights key abstracts focusing on clinical studies in CAR-T therapy in leukemia and lymphoma presented at the 61 st annual meeting of the American Society of Hematology (December 2019, Orlando, FL). Selected studies discuss data on novel CAR-T constructs aimed at enhancing efficacy and durability of responses, improving toxicity mitigation strategies, challenging clinical scenarios in routine clinical practice for standard of care CAR-T therapy (role of bridging therapy, CNS involvement, and quality of life studies), and new technologies aiming to decrease production time to minimize delay in definitive therapy, all within the rapidly-evolving cellular immunotherapy landscape.
嵌合抗原受体 T 细胞（CAR-T）疗法彻底改变了血液系统恶性肿瘤领域，为以前选择有限的患者带来了潜在的治愈希望。本篇综述重点介绍了在美国血液学会第 61 届年会上展示的 CAR-T 疗法治疗白血病和淋巴瘤的临床研究的关键摘要（2019 年 12 月，佛罗里达州奥兰多）。选定的研究讨论了旨在提高疗效和反应持久性、改善毒性缓解策略、应对常规临床实践中标准 CAR-T 疗法的挑战性临床情况（桥接治疗的作用、中枢神经系统受累和生活质量研究）以及旨在缩短生产时间以尽量减少确定性治疗延迟的新技术的新型 CAR-T 构建体的数据，所有这些都在快速发展的细胞免疫治疗领域内。
